Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Livingstone, C.
Right arrow Articles by Ferns, G. A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Insulin-like growth factor-related proteins and diabetic complications

Callum Livingstone

Peptide Hormone Supraregional Assay Service, Clinical Laboratory, Royal Surrey County Hospital, Guildford, Surrey, GU2 5XX, UK, clivingstone{at}royalsurrey.nhs.uk

Gordon Aa Ferns

Centre for Clinical Science and Measurement, School of Biomedical and Life Sciences, University of Surrey, Guildford, Surrey, GU2 7XX, UK

The insulin-like growth factor system and, in particular, insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-1 (IGFBP-1) are dysregulated in type 1 and type 2 diabetes. Serum IGF-I levels are low in both forms of diabetes, and this may be in part genetically determined. It is possible that the reduced serum levels of IGF-I are involved in the development of microvascular and macrovascular complications. Fasting serum IGFBP-1 levels are usually low in early type 2 diabetic patients with insulin resistance and hyperinsulinaemia but may be raised in patients with particularly poor glycaemic control and severe beta-cell failure. Treatment with IGF-I/binding protein complexes has been shown to improve glycaemic control in conjunction with insulin and may in future have a place in the treatment of diabetes, potentially to prevent diabetic complications. Serum IGFBP-1 determination may have utility in the assessment of cardiovascular risk and as an indicator for insulin resistance.

Key Words: insulin-like growth factor • insulin-like growth factor binding protein • diabetes • microvascular disease • macrovascular disease.

References

  • Froesch ER, Hussain MA, Schmid C., Zapf J. Insulin-like growth factor-I: physiology, metabolic effects and clinical uses. Diab Metab Rev 1996;12: 195-215.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Binoux M. The IGF system in metabolism regulation. Diab Metab 1995; 21:330-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Monzavi R., Cohen P. IGFs and IGFBPs: role in health and disease. Best Pract Clin Endocrinol Metab 2002;16:433-47.[CrossRef]
  • Boisclair YR, Rhoads RP, Ueki I., Wang J., Ooi GT The acid labile subunit (ALS) of the 150KDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170: 63-70.[Abstract]
  • Collett-Solberg PF, Cohen P. The role of insulin-like growth factor binding proteins and the IGFBP proteases in modulating IGF action. Endocrinol Metab Clin North Am 1996;25:591-614.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Feldmann B., Jehle PM, Mohan S. et al. Diabetic retinopathy is associated with decreased serum levels of free IGF-I and changes of IGF binding proteins. Growth Horm IGF Res 2000;10:53-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulinlike growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44:333-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holt RIG, Simpson HL, Sonksen PH The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diab Med 2003; 20:3-15.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Garay-Sevilla ME, Nava LE, Malacara JM, Wrobel K., Perez U. Advanced glycosylation end products, insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) in patients with type-2 diabetes mellitus. Diab Metab Res Rev 2000;16:106-13.[CrossRef]
  • Bang P., Nygren J., Carlsson-Skwirut C., Thorell A., Ljungqvist O. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 1998;83:2509-15.[Abstract/Free Full Text]
  • Clauson PG, Brismar K., Hall K., Linnarsson R., Grill V. Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type-2 diabetic patients in Sweden. Scand J Clin Lab Invest 1998;58:353-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chantelau E., Kohner EM Why some cases of retinopathy worsen when diabetic control improves. BMJ 1997;315:1105-06.[Free Full Text]
  • Henricsson M., Berntorp K., Fernlund P., Sundkvist G. Progression of retinopathy in insulin-treated type-2 diabetic patients. Diabetes Care 2002;25:381-5.[Abstract/Free Full Text]
  • Giannini S., Cresci B., Manuelli C. et al. Insulin-like growth factor binding protein production in bovine retinal endothelial cells. Metabolism 1997; 46:1367-79.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Janssen Jamjl, Lamberts SWJ. Circulating IGF-I and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol 2000;52:1-9.[CrossRef][Medline] [Order article via Infotrieve]
  • Simo R., Lecube A., Segura RM, Garcia-Arumi J., Hernandez C. Free insulin like growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002;134:376-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Simo R., Hernandez C., Segura RM et al. Free insulin-like growth factor-I in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case control study. Clin Sci 2003;104:223-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gibson JM, Westwood M., Lauszus FF, Klebe JG, Flyvbjerg A., White A. Phosphorylated insulin-like growth factor binding protein-1 is increased in pregnant diabetic subjects. Diabetes 1999;48:321-6.[Medline] [Order article via Infotrieve]
  • Jones JI, D'Ercole AJ, Camacho-Hubner C., Clemmons DR Phosphorylation of insulin-like growth factor (IGF)-binding protein-1 in cell culture and in vivo: effects on affinity for IGF-I. Proc Natl Acad Sci USA 1991;88:7481-5.[Abstract/Free Full Text]
  • Chiarelli F., Santilli F., Mohn A. Role of growth factors in the development of diabetic complications. Horm Res 2000;53:53-67.[Web of Science][Medline] [Order article via Infotrieve]
  • Crosby SR, Tsigos C., Anderton CD, Gordon C., Young RJ, White A. Elevated plasma insulin-like growth factor binding protein-1 levels in type-1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia 1992;35:868-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Grandis M., Nobbio L., Abbruzzese M. et al. Insulin treatment enhances expression of IGF-I in sural nerves from diabetic patients. Muscle Nerve 2001;24:622-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Russell JW, Feldman EL Insulin-like growth factor-I IGF-I prevents apoptosis in sympathetic neurons exposed to high glucose. Horm Metab Res 1999;31:90-6.[Web of Science][Medline] [Order article via Infotrieve]
  • Zhuang HX, Snyder CK, Pu SF, Ishii DN Insulin-like growth factors reverse or arrest diabetic neuropathy: effects on hyperalgesia and impaired nerve regeneration in rats. Experimental Neurology 1996;140:198-205.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Brand FN, Kannel WB, Evans J., Larson MG, Wolf PA Glucose intolerance, physical signs of peripheral artery disease and the risk of cardiovascular events: The Framingham study. Am Heart J 1998;136:919-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miettinen H., Lehto S., Salomaa V. et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998;21:6-75.
  • Hayden JM, Reaven PD Cardiovascular disease in diabetes mellitus type-2: a potential role for novel cardiovascular risk factors. Curr Op Lipidol 2000;11:519-28.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lee WL, Chen JW, Ting CT, Wang PH Changes of the insulin-like growth factor-I system during acute myocardial infarction: implications on left ventricular remodelling. J Clin Endocrinol Metab 1999;84:1575-81.[Abstract/Free Full Text]
  • Izhar U., Hasdai D., Richardson DM, Cohen P., Lerman A. Insulin and insulin-like growth factor-I cause vasorelaxation in human vessels in vitro. Coron Artery Dis 2000;11:69-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Montani A., Forster L., Tull S., Angaard EE, Ferns GAA. Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Path 1996;77:31-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zenobi PD, Holzmann P., Glatz Y., Riesen WF, Froesch ER Improvement of lipid profile in type-2 (non-insulin dependent) diabetes mellitus by insulin-like growth factor-I. Diabetologia 1993;36:465-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vaessen N., Heutink P., Janssen JA et al. A polymorphism in the gene for IGF-I: functional properties and risk for type-2 diabetes and myocardial infarction. Diabetes 2001;50:637-42.[Abstract/Free Full Text]
  • Janssen Jamjl, Lamberts SWJ. The role of IGF-I in the development of cardiovascular disease in type-2 diabetes mellitus: is prevention possible? Eur J Endocrinol 2002;146:467-77.[Abstract]
  • Rietveld I., Janssen JA, Hofman A., Pols HA, van Duijn CM, Lambert SW A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur J Endocrinol 2003;148:171-5.[Abstract]
  • Frayling TM, Hattersley AT, McCarthy AM et al. A putative functional polymorphism in the IGF-I gene. Association studies with type-2 diabetes, adult height, glucose tolerance and fetal growth in UK populations. Diabetes 2002;51:2313-16.[Abstract/Free Full Text]
  • Heald AH, Siddals KW, Fraser W. et al. Low circulating levels of insulin-like growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension in type-2 diabetes. Diabetes 2002;51:2629-36.[Abstract/Free Full Text]
  • Zarich SW, Nesto RW Diabetic cardiomyopathy. Am Heart J 1989;118: 1000-12.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Osterziel KJ, Rank MB, Strohm O., Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-I and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 2000;53:61-8.[CrossRef][Medline] [Order article via Infotrieve]
  • Norby FL, Wold LE, Duan J., Hintz KK, Ren J. IGF-I attenuates diabetesinduced cardiac dysfunction in ventricular myocytes. Am J Physiol Endocrinol Metab 2002;238:E658-E666.
  • Gibson JM, Westwood M., Young RJ et al. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996;81:860-3.[Abstract]
  • Heald AH, Cruickshank JK, Riste LK et al. Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 2001;44:333-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hellenius MB, Brismar KE, Berglund BH et al. Effects on glucose tolerance, insulin secretion, insulin-like growth factor-I and its binding protein, IGFBP-1 in a randomised controlled diet and exercise study in healthy middle aged men. J Int Med 1995;238:121-30.[Web of Science][Medline] [Order article via Infotrieve]
  • Lemne C., Brismar K. Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome: a study in borderline hypertension. Blood Press 1998;7:89-95.[Medline] [Order article via Infotrieve]
  • Saitoh H., Kamoda T., Nakahara S. et al. Insulin-like growth factor binding protein-1 as a predictor of glucose stimulated hyperinsulinaemia in pre-pubertal obese children. Eur J Endocrinol 1999;140:231-4.[Abstract]
  • Leinonen ES, Salonen JT, Salonen RM et al. Reduced IGFBP-1 is associated with thickening of the carotid wall in type-2 diabetes. Diabetes Care 2002;25:1807-12.[Abstract/Free Full Text]
  • Clark RG, Mortensen DL, Reifsynder D., Mohler M., Etcheverry T., Mukku V. Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3): effects on the glycaemic and growth promoting activities of rhIGF-I in the rat. Growth Regul 1993:3:50-2.[Web of Science][Medline] [Order article via Infotrieve]
  • Clark RG, Mortensen DL, Carlsson LM, Carlsson B., Carmignac D., Robinson IC The obese growth hormone (GH)-deficient dwarf rat: boy responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology 1996;137:1904-12.[Abstract]
  • Carroll PV, Umpleby M., Ward GS et al. rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion and improves the lipid profile in adults with IDDM. Diabetes 1997;46:1453-8.[Abstract]
  • 9. Cheetham TD, Connors M., Clayton K., Watts A., Dunger DB The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor (rhIGF-I). Clin Endo 1997;46:415-24.[CrossRef]
  • Thrailkill KM Insulin-like growth factor-I in diabetes mellitus: its physiological metabolic effects and potential clinical utility. Diab Technol Ther 2000;2:69-80.[CrossRef]
  • Quattrin T., Thrailkill K., Baker L. et al. Improvement of HbA1c without increased hypoglycaemia in adolescents and young adults with type-1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin/ rhIGF-I in IDDM study group. J Pediatr Endocrinol Metab 2001;14:267-77.[Web of Science][Medline] [Order article via Infotrieve]
  • Thrailkill KM, Quattrin T., Baker L. et al. Cotherapy with recombinant human insulin-like growth factor-I and insulin improves glycaemic control in type-1 diabetes. Diabetes Care 1999;22:585-92.[Abstract]
  • Clemmons DR, Moses AC, McKay MJ, Sommer A., Rosen DM, Ruckle J. The combination of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type-1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 2000;85:1518-24.[Abstract/Free Full Text]
  • Cusi K., DeFronzo R. Recombinant human insulin-like growth factor-I treatment improves metabolic control in type-2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 2000;85: 3077-84.[Abstract/Free Full Text]
  • Moses AC, Young SCJ, Morrow LA, O'Brien M., Clemmons DR Recombinant human IGF-I increases insulin sensitivity and improves glycaemic control in insulin requiring type-2 diabetes. Diabetes 1996;45: 91-100.[Abstract]
  • O'Connell T., Clemmons DR IGF-I/IGF-binding protein-3 combination improves insulin resistance by GH-dependent and independent mechanisms. J Clin Endocrinol Metab 2002;87:4356-60.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 5, 326-331 (2003)
DOI: 10.1177/14746514030030050301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Livingstone, C.
Right arrow Articles by Ferns, G. A.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?